JavaScript is disabled in your browser. You can still read and search, but features like search previews, menus, and forms may not work until it's enabled.

Psychedelic Therapy: A Primer for Primary Care Clinicians—5-Methoxy-N,N-Dimethyltryptamine

Burton J. Tabaac, Kenneth Shinozuka, Anne Weisman, Shiven Chaudhry, Mathieu Seynaeve, Owen S. Muir

American Journal of Therapeutics February 20, 2026 DOI: 10.1097/mjt.0000000000002106 (opens in new tab)

Relevant Not relevant

Study at a glance

AI-extracted from the abstract

Characteristics	Review Peer reviewed
Population	Treatment-resistant depression and other psychiatric conditions
Topics	5-MeO-DMT DMT Psychedelic-assisted therapy
Keywords	Primary care Primer cosmetics Depression economics Medline Primary health care Family medicine
Key findings	Emerging evidence supports 5-MeO-DMT as a promising treatment for treatment-resistant depression and other psychiatric conditions, warranting larger RCTs.

Abstract

Emerging evidence supports 5-MeO-DMT as a promising, ultra-short-acting psychedelic for treatment-resistant depression and other psychiatric conditions, warranting larger RCTs.